Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis

This study has been terminated.
Information provided by:
Allergan Identifier:
First received: June 2, 2006
Last updated: May 27, 2011
Last verified: May 2011
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.

Condition Intervention Phase
Anterior Uveitis
Drug: Dexamethasone
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Anterior Chamber Cell

Enrollment: 5
Study Start Date: May 2006
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older with a diagnosis of non-infectious anterior uveitis in at least one eye

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Any active ocular infections
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00333996

United States, Texas
Dallas, Texas, United States
Sponsors and Collaborators
Study Chair: Allergan Inc. Allergan
  More Information

Responsible Party: Therapeutic Area Head, Allergan, Inc Identifier: NCT00333996     History of Changes
Other Study ID Numbers: 206207-015 
Study First Received: June 2, 2006
Last Updated: May 27, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Uveitis, Anterior
Uveal Diseases
Eye Diseases
Iris Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on October 26, 2016